Tag Archives: Abiraterone

Abiraterone is a selective androgen biosynthesis inhibitor that blocks the action of CYP17.

Abiraterone acetate substantially prolonged overall survival in patients with castration-resistant metastatic prostate cancer that progressed on docetaxel-based chemotherapy. The favorable impact of abiraterone was consistent across all prespecified subgroups, using a similar survival benefit as inside the total population. These … Continue reading

Posted in Uncategorized | Tagged | Leave a comment

Abiraterone acetate compared with ten.9 months OS for patients

The approval is based on the results of a randomized placebo-controlled multicenter trial in 1195 patients with mCRPC previously treated with docetaxel-containing regimens. Patients had been randomly assigned (2:1) to obtain either abiraterone acetate orally at a dose of 1000 … Continue reading

Posted in Uncategorized | Tagged | Leave a comment